T. Rowe Price Associates’s Harmony Biosciences HRMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.1M | Buy |
34,832
+4,993
| +17% | +$158K | ﹤0.01% | 1947 |
|
|
2025
Q1 | $991K | Buy |
29,839
+10,051
| +51% | +$334K | ﹤0.01% | 1961 |
|
|
2024
Q4 | $681K | Buy |
19,788
+4,911
| +33% | +$169K | ﹤0.01% | 2140 |
|
|
2024
Q3 | $596K | Buy |
14,877
+185
| +1% | +$7.41K | ﹤0.01% | 2181 |
|
|
2024
Q2 | $444K | Buy |
14,692
+473
| +3% | +$14.3K | ﹤0.01% | 2235 |
|
|
2024
Q1 | $478K | Buy |
14,219
+1,201
| +9% | +$40.4K | ﹤0.01% | 2229 |
|
|
2023
Q4 | $421K | Buy |
13,018
+620
| +5% | +$20.1K | ﹤0.01% | 2250 |
|
|
2023
Q3 | $407K | Buy |
12,398
+717
| +6% | +$23.5K | ﹤0.01% | 2207 |
|
|
2023
Q2 | $412K | Buy |
11,681
+1,628
| +16% | +$57.4K | ﹤0.01% | 2218 |
|
|
2023
Q1 | $329K | Buy |
10,053
+454
| +5% | +$14.9K | ﹤0.01% | 2298 |
|
|
2022
Q4 | $529K | Buy |
9,599
+357
| +4% | +$19.7K | ﹤0.01% | 2103 |
|
|
2022
Q3 | $410K | Buy |
9,242
+1,740
| +23% | +$77.2K | ﹤0.01% | 2225 |
|
|
2022
Q2 | $366K | Buy |
7,502
+437
| +6% | +$21.3K | ﹤0.01% | 2352 |
|
|
2022
Q1 | $344K | Buy |
7,065
+500
| +8% | +$24.3K | ﹤0.01% | 2484 |
|
|
2021
Q4 | $280K | Buy |
+6,565
| New | +$280K | ﹤0.01% | 2610 |
|
|
2020
Q4 | – | Sell |
-209,361
| Closed | -$7.1M | – | 2691 |
|
|
2020
Q3 | $7.1M | Buy |
+209,361
| New | +$7.1M | ﹤0.01% | 1363 |
|